Skip to main navigation Skip to search Skip to main content

Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

  • Y Li*
  • , GL Yang
  • , HY Yuan
  • , DJ Bai
  • , K Wang
  • , CR Lin
  • , MB Hu
  • , MH Feng
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

["Background/Aims: Cimetidine (CIM) seems to have positive effects on the immune systems of cancer patients. This study was conducted to investigate the effects of perioperative administration of CIM on the peripheral blood lymphocytes, natural killer (NK) cells and tumor infiltrating lymphocytes (TIL) in patients with gastrointestinal (GI) cancer.","Methodology: Forty-nine GI cancer patients-were randomized into a treatment group which took CIM in the perioperative period, and a control group which did not take, the drug. The treatment was initiated 7 days (d) before operation and continued until 10 d after surgery. At baseline examination, before operation, on the 2nd and the 10th postoperative d, peripheral blood T lymphocytes, helper T cells, T suppressor cells, and NK cells were measured by immunocytochemical method. The surgical specimens were examined for TIL response, and immunohistochemical study was performed to measure the proportion of T and B lymphocytes in the TIL population.","Results: In comparison with normal controls, both the treatment and the control groups had decreased T cells, helper T cells and NK cells at baseline. In the control group, total T cells, helper T cells and NK cells declined progressively with the disease course and the decreases became more profound after operation. From the baseline to the 2nd postoperative d, the proportion of total T cells, helper T cells, and NK cells went down from 60.5 +/- 4.6 to 56.2 +/- 3.8 percent, from 33.4 +/- 3.7 to 28.1 +/- 3.4 percent, and from 15.0 +/- 2.8 to 14.2 +/- 2.2 percent, respectively. On the other hand, there were significant improvements in these parameters after CIM treatment. On the 10th postoperative d, the treatment group had significantly higher percentages of total T cells, helper T cells and NK cells than control group. Moreover, CIM treatment also boosted the TIL response, as was reflected by findings that 68% (17/25) of the patients in the treatment group had significant TIL responses and only 25% (6/24) of the cases had discernible TIL response.","Conclusions: Perioperative application of CIM to GI cancer patients could help restore the diminished cellular immunity boost TIL responses to tumor."]
Original languageEnglish
Pages (from-to)504-508
Number of pages5
JournalHepato-Gastroenterology
Volume52
Issue number62
StatePublished - Mar 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Indexed by

  • SCIE

Fingerprint

Dive into the research topics of 'Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial'. Together they form a unique fingerprint.

Cite this